168 related articles for article (PubMed ID: 38675717)
1. Development of Glycosylation-Modified
Deng P; Dong X; Wu Z; Hou X; Mao L; Guo J; Zhao W; Peng C; Zhang Z; Peng L
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675717
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Evaluation of
OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
[TBL] [Abstract][Full Text] [Related]
5. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
[TBL] [Abstract][Full Text] [Related]
6. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
[TBL] [Abstract][Full Text] [Related]
7. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
Front Immunol; 2021; 12():737076. PubMed ID: 34659228
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage.
Song Z; Liu B; Peng X; Gu W; Sun Y; Xing L; Xu Y; Geng M; Ai J; Zhang A
J Med Chem; 2021 Nov; 64(22):16687-16702. PubMed ID: 34761679
[TBL] [Abstract][Full Text] [Related]
9. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
[TBL] [Abstract][Full Text] [Related]
10. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.
Wang F; Ye W; He Y; Zhong H; Zhu Y; Han J; Gong X; Tian Y; Wang Y; Wang S; Ji S; Liu H; Yao X
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835382
[TBL] [Abstract][Full Text] [Related]
11. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Yang Y; Wang K; Chen H; Feng Z
Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
[TBL] [Abstract][Full Text] [Related]
14. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
15. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
16. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
17. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
18. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
[TBL] [Abstract][Full Text] [Related]
19. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
Fujiwara K; Shigematsu K; Tachibana M; Okada N
IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]